Medtronic's Collins confident of 15% CAGR (compounded annual growth rate) - without acquisitions
This article was originally published in Clinica
Medtronic unveiled its five-year plan for growth yesterday, telling analysts that despite its size and dominance of the medical device market it will comfortably achieve a 15% compounded annual growth rate by focusing on its potentially large but still under-penetrated major markets.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.